Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease

2014 ◽  
Vol 42 (3) ◽  
pp. 901-908 ◽  
Author(s):  
Anna Antonell ◽  
Alicia Mansilla ◽  
Lorena Rami ◽  
Albert Lladó ◽  
Alex Iranzo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Fluid Level ◽  
Cerebrospinal Fluid Level ◽  
Prodromal Alzheimer’S Disease

Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease

2013 ◽  
Vol 38 (7) ◽  
pp. 1058-1066 ◽  
Author(s):  
Per Johansson ◽  
Erik G. Almqvist ◽  
Jan-Ove Johansson ◽  
Niklas Mattsson ◽  
Oskar Hansson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Fluid Level ◽  
Cerebrospinal Fluid Level

Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer’s Disease

2015 ◽  
Vol 48 (3) ◽  
pp. 637-646 ◽  
Author(s):  
Daniel Åberg ◽  
Per Johansson ◽  
Jörgen Isgaard ◽  
Anders Wallin ◽  
Jan-Ove Johansson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Fluid Level ◽  
Cerebrospinal Fluid Level ◽  
Factor Ii ◽  
Male Patients

scholarly journals On the design of early-phase Alzheimer’s disease clinical trials with cerebrospinal fluid tau outcomes

2021 ◽  
pp. 174077452110344
Author(s):  
Michelle M Nuño ◽  
Joshua D Grill ◽  
Daniel L Gillen ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cerebrospinal Fluid ◽  
Phosphorylated Tau ◽  
Inclusion Criteria ◽  
Eligibility Criteria ◽  
Total Tau ◽  
Prodromal Alzheimer’S Disease ◽  
Study Power

Background/Aims: The focus of Alzheimer’s disease studies has shifted to earlier disease stages, including mild cognitive impairment. Biomarker inclusion criteria are often incorporated into mild cognitive impairment clinical trials to identify individuals with “prodromal Alzheimer’s disease” to ensure appropriate drug targets and enrich for participants likely to develop Alzheimer’s disease dementia. The use of these eligibility criteria may affect study power. Methods: We investigated outcome variability and study power in the setting of proof-of-concept prodromal Alzheimer’s disease trials that incorporate cerebrospinal fluid levels of total tau (t-tau) and phosphorylated (p-tau) as primary outcomes and how differing biomarker inclusion criteria affect power. We used data from the Alzheimer’s Disease Neuroimaging Initiative to model trial scenarios and to estimate the variance and within-subject correlation of total and phosphorylated tau. These estimates were then used to investigate the differences in study power for trials considering these two surrogate outcomes. Results: Patient characteristics were similar for all eligibility criteria. The lowest outcome variance and highest within-subject correlation were obtained when phosphorylated tau was used as an eligibility criterion, compared to amyloid beta or total tau, regardless of whether total tau or phosphorylated tau were used as primary outcomes. Power increased when eligibility criteria were broadened to allow for enrollment of subjects with either low amyloid beta or high phosphorylated tau. Conclusion: Specific biomarker inclusion criteria may impact statistical power in trials using total tau or phosphorylated tau as the primary outcome. In concert with other important considerations such as treatment target and population of clinical interest, these results may have implications to the integrity and efficiency of prodromal Alzheimer’s disease trial designs.

Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease

2005 ◽  
Vol 57 (6) ◽  
pp. 832-842 ◽  
Author(s):  
Masahiro Maruyama ◽  
Makoto Higuchi ◽  
Yoshie Takaki ◽  
Yukio Matsuba ◽  
Haruko Tanji ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Prodromal Alzheimer’S Disease

Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease

2020 ◽  
Vol 715 ◽  
pp. 134658 ◽  
Author(s):  
Lijun Wang ◽  
Tianhao Gao ◽  
Tengteng Cai ◽  
Kunyi Li ◽  
Ping Zheng ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cerebrospinal Fluid Levels ◽  
Prodromal Alzheimer’S Disease ◽  
Fluid Levels

Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease

2012 ◽  
Vol 516 (2) ◽  
pp. 302-305 ◽  
Author(s):  
M. Kosicek ◽  
H. Zetterberg ◽  
N. Andreasen ◽  
J. Peter-Katalinic ◽  
S. Hecimovic
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Prodromal Alzheimer’S Disease

scholarly journals Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease

2018 ◽  
Vol 71 ◽  
pp. 81-90 ◽  
Author(s):  
Niklas Mattsson ◽  
Oscar Eriksson ◽  
Olof Lindberg ◽  
Michael Schöll ◽  
Björn Lampinen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Apoe Ε4 ◽  
Cerebrospinal Fluid Biomarkers ◽  
Prodromal Alzheimer’S Disease
Sign in / Sign up

Export Citation Format

Share Document